Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
Authors
Keywords
Raltegravir, Tipranavir, Liver enzymes, Transaminases
Journal
AIDS Research and Therapy
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-04-02
DOI
10.1186/s12981-016-0101-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV–hepatitis C virus coinfected patients
- (2012) Eugenia Vispo et al. AIDS
- Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients
- (2012) Catherine Fagard et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial
- (2011) Lauriane Goldwirt et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-Term Safety from the Raltegravir Clinical Development Program
- (2011) Hedy Teppler et al. CURRENT HIV RESEARCH
- Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection
- (2011) JK Rockstroh et al. HIV MEDICINE
- Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
- (2011) Sébastien Gallien et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV‐Infected Persons without Hepatitis B or C Virus Co‐Infection
- (2010) Helen Kovari et al. CLINICAL INFECTIOUS DISEASES
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Clinical syndromes and consequences of antiretroviral-related hepatotoxicity
- (2010) Marina Núñez HEPATOLOGY
- Antiretroviral drugs and liver injury
- (2009) Vincent Soriano et al. AIDS
- Hepatic profile analyses of tipranavir in Phase II and III clinical trials
- (2009) Jaromir Mikl et al. BMC INFECTIOUS DISEASES
- Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial
- (2009) Nathalie De Castro et al. CLINICAL INFECTIOUS DISEASES
- Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis
- (2008) J. Macias et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search